Redhill Biopharma (RDHL) Stock Price, News & Analysis

Company Overview

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Key Stats

• Today's Range: $1.78 to $1.84
• 50-Day Range: $1.75 to $2.41
• 52-Week Range: $1.71 to $20.28
• Volume: 10,888 shs
• Average Volume: 162,998 shs
• Market Capitalization: $4.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RDHL Stock Analysis - Frequently Asked Questions

How have RDHL shares performed this year?

Redhill Biopharma's stock was trading at $6.21 on January 1st, 2025. Since then, RDHL stock has decreased by 70.4% and is now trading at $1.84.
View the best growth stocks for 2025 here.

How were Redhill Biopharma's earnings last quarter?

Redhill Biopharma Ltd. (NASDAQ:RDHL) released its quarterly earnings results on Tuesday, November, 30th. The biotechnology company reported ($500.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($480.00) by $20.00. The biotechnology company had revenue of $21.61 million for the quarter, compared to analyst estimates of $23.41 million.

When did Redhill Biopharma's stock split?

Redhill Biopharma's stock reverse split before market open on Tuesday, August 20th 2024. The 1-25 reverse split was announced on Friday, August 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 19th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of Redhill Biopharma?

Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Redhill Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Redhill Biopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), CymaBay Therapeutics (CBAY) and AbbVie (ABBV).

Company Calendar

• Last Earnings: 11/30/2021
• Today: 6/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RDHL
• Previous Symbol: ASX:RDH
• CIK: 1553846
• Web: www.redhillbio.com
• Phone: 972-3541-3131
• Fax: 972-3541-3144
• Employees: 210
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.54
• Quick Ratio: 0.37

Sales & Book Value

• Annual Sales: $8.04 million
• Price / Sales: 0.52
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.66) per share
• Price / Book: -0.50

Miscellaneous

• Outstanding Shares: 2,290,000
• Free Float: 2,136,000
• Market Cap: $4.21 million
• Optionable: No Data
• Beta: 4.22